NO20092023L - Oligoribonuleotider og anvendelser derav - Google Patents

Oligoribonuleotider og anvendelser derav

Info

Publication number: NO20092023L
Authority: NO; Norway
Prior art keywords: orn; moiety; poly; immunostimulatory; oligoribonuleotides
Prior art date: 2006-10-26

Application number

NO20092023A

Other languages

English (en)

Norwegian (no)

Inventor

Eugen Uhlmann

Marion Jurk

Jorg Vollmer

Original Assignee

Coley Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-26

Filing date

2009-05-25

Publication date

2009-06-23

2009-05-25 Application filed by Coley Pharm Gmbh filed Critical Coley Pharm Gmbh

2009-06-23 Publication of NO20092023L publication Critical patent/NO20092023L/no

Links

230000003308 immunostimulating effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3511—Conjugate intercalating or cleaving agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20092023A 2006-10-26 2009-05-25 Oligoribonuleotider og anvendelser derav NO20092023L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US85458506P	2006-10-26	2006-10-26
PCT/IB2007/004593 WO2008139262A2 (en)	2006-10-26	2007-10-26	Oligoribonucleotides and uses thereof

Publications (1)

Publication Number	Publication Date
NO20092023L true NO20092023L (no)	2009-06-23

Family

ID=40002694

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20092023A NO20092023L (no)	2006-10-26	2009-05-25	Oligoribonuleotider og anvendelser derav

Country Status (13)

Country	Link
US (1)	US20100144846A1 (pt)
EP (1)	EP2104738A2 (pt)
JP (1)	JP2010507386A (pt)
KR (1)	KR20090058584A (pt)
CN (1)	CN101558157A (pt)
AU (1)	AU2007353120A1 (pt)
BR (1)	BRPI0718182A2 (pt)
CA (1)	CA2667297A1 (pt)
MX (1)	MX2009004510A (pt)
NO (1)	NO20092023L (pt)
RU (1)	RU2009115687A (pt)
WO (1)	WO2008139262A2 (pt)
ZA (1)	ZA200902823B (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en)	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DK1733735T3 (en)	1998-05-22	2017-06-19	Ottawa Hospital Res Inst	Methods and products for the induction of mucosal immunity
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
ES2314099T3 (es)	2001-08-17	2009-03-16	Coley Pharmaceutical Gmbh	Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
CA2480775C (en)	2002-04-04	2016-05-31	Coley Pharmaceutical Gmbh	Immunostimulatory g,u-containing oligoribonucleotides
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
CA2503693A1 (en)	2002-10-29	2004-05-13	Coley Pharmaceutical Group, Ltd.	Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
JP2006512927A (ja)	2002-12-11	2006-04-20	コーリーファーマシューティカルグループ，インコーポレイテッド	５’ｃｐｇ核酸およびその使用方法
CN101454451A (zh)	2003-10-30	2009-06-10	科勒制药有限公司	具有增强免疫刺激能力的c类寡核苷酸类似物
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
JP2010507361A (ja) *	2006-07-31	2010-03-11	キュアバックゲーエムベーハー	具体的には免疫刺激剤／アジュバントとしての、一般式（Ｉ）：ＧｌＸｍＧｎ、または一般式（ＩＩ）：ＣｌＸｍＣｎで表される核酸
CN101517082B (zh)	2006-09-27	2014-01-22	科勒制药有限责任公司	具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
CN101932707B (zh) *	2008-01-31	2013-08-21	库瑞瓦格有限责任公司	作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物
SG171914A1 (en)	2008-12-02	2011-07-28	Chiralgen Ltd	Method for the synthesis of phosphorus atom modified nucleic acids
MX2011008383A (es) *	2009-02-10	2011-09-06	Idera Pharmaceuticals Inc	Agonistas basados en acido ribonucleico sintetico de receptor 7 tipo toll.
AU2010225129A1 (en) *	2009-03-17	2010-09-23	Gunther Hartmann	TLR7 ligand and uses thereof
GB0910723D0 (en) *	2009-06-22	2009-08-05	Sylentis Sau	Novel drugs for inhibition of gene expression
EP2451461A4 (en)	2009-07-06	2013-05-29	Ontorii Inc	NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
DK2620428T3 (da)	2010-09-24	2019-07-01	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
CA2821622C (en) *	2010-12-16	2019-09-03	Sprna Gmbh	Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
US9605019B2 (en)	2011-07-19	2017-03-28	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
US20140286998A1 (en) *	2011-10-31	2014-09-25	Riboxx Gmbh	Double-Stranded RNA For Immunostimulation
WO2013151771A1 (en)	2012-04-05	2013-10-10	Massachusetts Institute Of Technology	Immunostimulatory compositions and methods of use thereof
JP6246121B2 (ja)	2012-07-13	2017-12-13	株式会社新日本科学	キラル核酸アジュバント
DK2872485T3 (da)	2012-07-13	2021-03-08	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
CN112007045B (zh)	2012-07-13	2026-01-06	波涛生命科学有限公司	手性控制
US10322173B2 (en)	2014-01-15	2019-06-18	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (en)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR102423317B1 (ko)	2014-01-16	2022-07-22	웨이브 라이프 사이언시스 리미티드	키랄 디자인
WO2016152767A1 (ja) *	2015-03-20	2016-09-29	国立研究開発法人医薬基盤・健康・栄養研究所	免疫賦活活性を有するＣｐＧスペーサーオリゴヌクレオチド含有複合体及びその用途
WO2017065369A1 (ko) *	2015-10-15	2017-04-20	한국과학기술원	Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제
KR101899057B1 (ko) *	2015-10-15	2018-09-14	한국과학기술원	Rna 올리고뉴클레오티드를 포함하는 암 치료용 약학 조성물
JP7145853B2 (ja) *	2016-11-09	2022-10-03	ザボードオブリージェンツオブザユニバーシティーオブテキサスシステム	適応免疫調節のための方法および組成物
EP3941511A2 (en)	2019-03-20	2022-01-26	Massachusetts Institute of Technology	Uses of amphiphiles in immune cell therapy and compositions therefor
CN114057816B (zh) *	2020-07-30	2025-02-11	浙江柏拉阿图医药科技有限公司	富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
EP4104830A1 (en)	2021-06-16	2022-12-21	Burghardt Wittig	Sequential innate and adaptive immune modulation for cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL107150A0 (en) *	1992-09-29	1993-12-28	Isis Pharmaceuticals Inc	Oligonucleotides having a conserved g4 core sequence
WO1996002555A1 (en) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
WO1998037919A1 (en) *	1997-02-28	1998-09-03	University Of Iowa Research Foundation	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
AU7690898A (en) *	1997-05-20	1998-12-11	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
US6218371B1 (en) *	1998-04-03	2001-04-17	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
DE19935756A1 (de) *	1999-07-27	2001-02-08	Mologen Forschungs Entwicklung	Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
NZ517928A (en) *	1999-09-27	2004-09-24	Coley Pharm Gmbh	Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
ES2314099T3 (es) *	2001-08-17	2009-03-16	Coley Pharmaceutical Gmbh	Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
US20050187176A1 (en) *	2003-10-10	2005-08-25	Bates Paula J.	Method for inhibiting NF-kappa B signaling and use to treat or prevent human diseases
EP1899467A2 (en) *	2005-04-26	2008-03-19	Coley Pharmaceutical GmbH	Modified oligoribonucleotide analogs with enhances immunostimulatory activity
RU2008117439A (ru) *	2005-10-04	2009-11-10	Макджилл Юниверсити (Ca)	Аптамеры, содержащие модифицированные арабинозой нуклеотиды

2007
- 2007-10-26 RU RU2009115687/10A patent/RU2009115687A/ru unknown
- 2007-10-26 EP EP07874026A patent/EP2104738A2/en not_active Withdrawn
- 2007-10-26 CA CA002667297A patent/CA2667297A1/en not_active Abandoned
- 2007-10-26 MX MX2009004510A patent/MX2009004510A/es not_active Application Discontinuation
- 2007-10-26 US US12/447,107 patent/US20100144846A1/en not_active Abandoned
- 2007-10-26 WO PCT/IB2007/004593 patent/WO2008139262A2/en not_active Ceased
- 2007-10-26 CN CNA2007800399749A patent/CN101558157A/zh active Pending
- 2007-10-26 BR BRPI0718182-5A2A patent/BRPI0718182A2/pt not_active Application Discontinuation
- 2007-10-26 AU AU2007353120A patent/AU2007353120A1/en not_active Abandoned
- 2007-10-26 JP JP2009533983A patent/JP2010507386A/ja not_active Withdrawn
- 2007-10-26 KR KR1020097008487A patent/KR20090058584A/ko not_active Ceased
2009
- 2009-04-23 ZA ZA200902823A patent/ZA200902823B/xx unknown
- 2009-05-25 NO NO20092023A patent/NO20092023L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2007353120A1 (en)	2008-11-20
EP2104738A2 (en)	2009-09-30
WO2008139262A8 (en)	2009-03-12
RU2009115687A (ru)	2010-11-10
US20100144846A1 (en)	2010-06-10
JP2010507386A (ja)	2010-03-11
CN101558157A (zh)	2009-10-14
BRPI0718182A2 (pt)	2014-02-25
KR20090058584A (ko)	2009-06-09
WO2008139262A3 (en)	2009-06-04
ZA200902823B (en)	2010-03-31
WO2008139262A2 (en)	2008-11-20
CA2667297A1 (en)	2008-11-20
MX2009004510A (es)	2009-05-12

Legal Events

Date	Code	Title	Description
2011-05-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
MX2009004510A (es)	2009-05-12	Oligorribonucleotidos y sus usos.
IL188475A0 (en)	2008-04-13	Pyrido [2,3-d]pyrimidine-2,4-diamine compounds as ptpib inhibitors
WO2008100805A3 (en)	2008-10-09	Anti-robo4 antibodies and uses therefor
TW200716646A (en)	2007-05-01	(S)-N-methylnaltrexone
NO20073875L (no)	2007-10-18	Krystallformer av 1-klor-4-(B-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzyl]-benzen, metode for fremstilling samt anvendelse for fremstilling av medikamenter
ECSP10010095A (es)	2010-07-30	2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
WO2006086449A3 (en)	2007-07-05	Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
UA99924C2 (en)	2012-10-25	Benzylbenzol derivatives and using thereof
WO2009041832A3 (en)	2009-06-11	Vaccines and vaccine components for inhibition of microbial cells
NO20091748L (no)	2009-07-14	Mikroorganismer eller fraksjoner derav, istand til aktivering avcellulaer immunitet mot karbohydrater
NO20080745L (no)	2008-04-09	Nye peptider for anvendelse i behandling av fedme
WO2007109236A8 (en)	2008-07-03	Microrna fingerprints during human megakaryocytopoiesis
BRPI0616630B8 (pt)	2021-05-25	compostos de pirazol substituídos
WO2011046964A3 (en)	2011-08-25	Inhibitors of bruton's tyrosine kinase
UA85559C2 (en)	2009-02-10	Aminobenzophenone compounds
WO2007047408A3 (en)	2009-04-30	Promac signature application
EA200801560A1 (ru)	2008-12-30	Бифенилкарбоксамиды
WO2006009765A3 (en)	2006-05-11	Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
EA201101015A1 (ru)	2012-02-28	Способ получения бивалирудина
EA200700717A1 (ru)	2007-10-26	Сульфонамиды
WO2009030770A3 (en)	2009-05-07	Methods and tools for prognosis of cancer in er- patients
WO2008067408A3 (en)	2008-11-20	Method of isolating and propagating stem cells from benign tumors
WO2009027978A8 (en)	2009-06-11	NUCLEIC ACID SEQUENCES COMPRISING NF-&kappav;B BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2007120955A3 (en)	2008-02-14	Genes affecting human memory performance
WO2005001039A3 (en)	2006-02-02	Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof